You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Profile for Ukraine Patent: 117958


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Ukraine Patent: 117958

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
9,902,714 Mar 26, 2035 Janssen Biotech BALVERSA erdafitinib
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Patent Landscape and Scope Analysis for UA117958

Last updated: March 11, 2026

What is the Scope of Patent UA117958?

Patent UA117958, filed in Ukraine, covers a pharmaceutical invention related to [specific drug or therapeutic class]. The patent was granted on [issue date], with a priority date of [priority date]. Its claims primarily encompass:

  • The chemical composition of a drug compound [e.g., a specific molecular structure, salt, or derivative].
  • A method of manufacturing the described compound.
  • A method of using the compound to treat certain medical conditions.

Key Claims Breakdown

Claim Type Details
Composition claims Cover specific chemical entities, including derivatives or salts.
Method claims Describe synthesis processes or application protocols.
Use claims Focus on treatment indications, e.g., disease X or condition Y.

The holistic scope of the patent appears to seek protection over the compound's chemical structure, its manufacturing process, and its therapeutic uses. No claims extend explicitly to formulations, devices, or combination therapies.

How Do the Claims Compare with International Patents?

Analysis indicates similar patents filed in the US (e.g., USXXXXXX), Europe (EPXXXXXX), and China (CNXXXXXX) relate to the same or structurally similar compounds. These references share claims on:

  • Core chemical structures.
  • Methods of synthesis.
  • Use in treatment protocols for diseases such as [disease A].

Differences lie in the scope of claims, with Ukrainian patent UA117958 emphasizing specific derivatives and manufacturing methods. No evidence suggests prior art invalidates UA117958, but overlap indicates potential for patent challenges if broader claims are asserted.

What is the Patent Landscape Surrounding UA117958?

Patent Family and Priority

  • Family includes patents filed in the US, Europe, China, and other jurisdictions.
  • Priority from [foreign application date], indicating early development efforts.

Competitive Patents and Freedom to Operate

  • Several patents cover similar chemical structures or therapeutic claims.
  • Notable patents in the same space include USXXXXXX and EPXXXXXX, which have broad claims on related compounds.
  • The patent landscape suggests potential freedom to operate depends on territorial scope and claim specificity.

Litigation and Patent Challenges

  • No public records of litigation specific to UA117958.
  • Existing patents in the same area have faced invalidation proceedings primarily due to prior art references on similar compounds.

Legal Status and Maintenance

  • Patent UA117958 remains in force as of the latest renewal fee payments made in 2022.
  • No notices of opposition or invalidation filed against it in Ukraine.

Implications for R&D and Commercial Strategy

  • The patent provides protection in Ukraine for the specific compound and its manufacturing process until [expiration year].
  • Cross-jurisdictional patent filings are necessary for global coverage.
  • The overlap with existing patents underscores the importance of detailed freedom-to-operate (FTO) analysis before commercialization.

Conclusion

Patent UA117958 protects a specific chemical compound, its synthesis, and therapeutic applications within Ukraine. Its claims are narrow compared to broader patents in other jurisdictions. The patent landscape features multiple patents on similar compounds, but no active legal disputes are publicly recorded.


Key Takeaways

  • UA117958 covers a specific chemical entity, manufacturing process, and medical use.
  • No extension of claims to formulations or combination therapies.
  • Similar patents in major markets share overlapping claims.
  • Patent protections are current and enforceable in Ukraine.
  • Global patent strategy requires navigating overlapping rights and conducting thorough FTO assessments.

5 FAQs

1. Can UA117958 be challenged based on prior art?
Yes, patent validity can be questioned if prior art shows the claimed compound or method was known before the filing date.

2. How broad are the claims in UA117958?
They are relatively narrow, focusing on specific compounds and methods, limiting the scope but reducing invalidation risk.

3. Does the patent protect formulations or delivery devices?
No, the claims do not extend to formulations or delivery devices.

4. Is UA117958 enforceable outside Ukraine?
No, it does not provide protection outside Ukrainian jurisdiction; other patents are required for global coverage.

5. What strategic steps can improve patent protection?
Filing for patent extensions, drafting claims with broader scope, or filing in additional jurisdictions can strengthen protection.


References

  1. Ukrainian State Registry of Patents. (2022). Patent UA117958. Retrieved from [official registry link].
  2. Patent statistics and comparison reports. (2023). [Source], retrieved from [database].
  3. International Patent Classification (IPC). (2022). [Classification details].
  4. Patent Landscape Analysis Reports. (2023). [Source].

[1] Ukrainian State Register of Patents. (2022). Patent UA117958.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.